Winter News 2013 - Beating Bowel Cancer
Winter News 2013 - Beating Bowel Cancer
Winter News 2013 - Beating Bowel Cancer
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Care and support<br />
Patient Services<br />
National Colorectal <strong>Cancer</strong> Nurses<br />
Network Conference<br />
In October we were delighted to<br />
organise the National Colorectal<br />
<strong>Cancer</strong> Nurses Network’s annual<br />
conference in London, which was attended by 70<br />
colorectal and stoma nurses.<br />
The delegates were given presentations on a wide<br />
variety of subjects ranging from the <strong>Cancer</strong> Drugs<br />
Fund to bowel management after rectal cancer to selfmanagement<br />
pathways. To wind up a very successful<br />
day of learning and networking, one of our <strong>Bowel</strong><br />
<strong>Cancer</strong> Voices, Hazel Elkamouri, gave a patient<br />
perspective on the challenges of coping with advanced<br />
bowel cancer.<br />
What the nurses valued most from the day was the<br />
opportunity to network with other colleagues and share<br />
experiences.<br />
New Chemotherapy Drugs<br />
There are two new drugs<br />
in the pipeline to treat<br />
advanced bowel cancer;<br />
both have been licenced<br />
by the US Food & Drug<br />
Administration, and await<br />
approval here in the UK.<br />
Zaltrap (aflibercept) is<br />
a targeted therapy which<br />
aims to block the growth<br />
of blood vessels to<br />
tumours (angiogenesis).<br />
In a large study of patients<br />
with previously treated<br />
advanced bowel cancer,<br />
aflibercept in combination<br />
with chemotherapy<br />
(FOLFIRI) was shown<br />
to help some patients<br />
to live longer.<br />
Stivarga (regorafenib)<br />
is an oral medicine which<br />
targets key proteins that<br />
are essential for the<br />
survival of the cancer cell.<br />
By specifically targeting<br />
these proteins, regorafenib<br />
may stop cancer growth or<br />
reduce the growth of the<br />
tumour.<br />
There are clinical trials<br />
available for both of these<br />
drugs – contact us if you<br />
would like further details.<br />
New Member<br />
of our Medical<br />
Advisory Board<br />
We are delighted to<br />
welcome to our<br />
Medical Advisory Board<br />
Mr Hassan Z Malik, a<br />
consultant hepatobiliary<br />
surgeon and clinical lead<br />
for liver surgery at<br />
University Hospital<br />
Aintree. Appointed to<br />
the hospital in 2007, he<br />
has introduced complex<br />
liver surgical techniques<br />
within the unit and his<br />
areas of clinical interest<br />
include the management<br />
of colorectal liver<br />
metastases.<br />
Mr Hassan Z Malik<br />
Consultant hepatobiliary<br />
surgeon and clinical lead for<br />
liver surgery at University<br />
Hospital Aintree.<br />
www.beatingbowelcancer.org 9